Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination

Vaccine

Volumn 29, Issue 5, 2011, Pages 913-919

  Koenig, Helen C ^a   Sutherland, Andrea ^a   Izurieta, Hector S ^a   McGonagle, Dennis ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Autoimmune diseases; Immunological disease continuum; Vaccine adverse events; Vaccine safety surveillance

Indexed keywords

VACCINE;

ADAPTIVE IMMUNITY; ALLERGIC REACTION; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GENETIC PREDISPOSITION; HUMAN; HUMORAL IMMUNITY; IMMUNE COMPLEX DISEASE; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NEUTROPHIL; PRIORITY JOURNAL; VACCINATION;

AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; VACCINATION; VACCINES;

EID: 78751566648     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.044     Document Type: Article

References (99)

1. Dyer O. Wakefield tells GMC he was motivated by concern for autistic children. BMJ 2008, 336:738.
2. McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med 2006, 3:e297.
3. International conference on harmonisation; guidance on statistical principles for clinical trials; availability - FDA. Notice. Fed Regist 1998, 63:49583-49598.
4. MedDRA (Medical Dictionary for Regulatory Activities), Regulatory Mandate Status Update, 2010; 2009.
5. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23:287-294.
6. Black S., Eskola J., Siegrist C.A., Halsey N., Macdonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009, 374:2115-2122.
7. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003, 52:1-24.
8. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
9. Institute of Medicine, Measles and Mumps Vaccines Adverse events associated with childhood vaccines: evidence bearing on causality 1994, 118-186. National Academy Press, Washington, DC. K.R. Stratton, C.J. Howe, R.B. Johnston (Eds.).
10. France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008, 121:e687-e692.
11. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110:105-123.
12. Institute of Medicine (IOM) Immunization safety review. Influenza vaccines and neurological complications 2003, National Academy Press, Washington, DC.
13. Eseverri J.L., Ranea S., Marin A. Adverse reactions to vaccines. Allergol Immunopathol (Madr) 2003, 31:125-138.
14. Ponvert C., Scheinmann P. Vaccine allergy and pseudo-allergy. Eur J Dermatol 2003, 13:10-15.
15. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
16. Clavel G., Grados F., Lefauveau P., Fardellone P. Osteoarticular side effects of BCG therapy. Joint Bone Spine 2006, 73:24-28.
17. Lane R.D., Bolte R.G. Pediatric anaphylaxis. Pediatr Emerg Care 2007, 23. 49, 56; quiz 57-60.
18. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112:815-820.
19. Trollmo C., Carlsten H., Tarkowski A. Intra-articular immunization induces strong systemic immune response in humans. Clin Exp Immunol 1990, 82:384-389.
20. U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting Presentations 2009.
21. McGonagle D., Aziz A., Dickie L.J., McDermott M.F. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 2009.
22. Zeher M., Szegedi G. Types of autoimmune disorders. Classification. Orv Hetil 2007, 148(Suppl. 1):21-24.
23. Bhat R., Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009, 64:123-132.
24. Irani S., Lang B. Autoantibody-mediated disorders of the central nervous system. Autoimmunity 2008, 41:55-65.
25. Menge T., Hemmer B., Nessler S., Wiendl H., Neuhaus O., Hartung H.P., et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005, 62:1673-1680.
26. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345:340-350.
27. Holgate S.T. Has the time come to rethink the pathogenesis of asthma?. Curr Opin Allergy Clin Immunol 2009.
28. Ben Dhifallah I., Lachheb J., Houman H., Hamzaoui K. Toll-like-receptor gene polymorphisms in a Tunisian population with Behcet's disease. Clin Exp Rheumatol 2009, 27:S58-S62.
29. Ozen S. The "other" vasculitis syndromes and kidney involvement. Pediatr Nephrol 2009.
30. Macaubas C., Nguyen K., Deshpande C., Phillips C., Peck A., Lee T., et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 2009.
31. Vavricka S.R., Rogler G. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options?. Swiss Med Wkly 2009, 139:527-534.
32. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009, 27:621-668.
33. McGonagle D., Georgouli T. The importance of 'Mechnikov's thorn' for an improved understanding of 21st century medicine and immunology: a view from the eye. Scand J Immunol 2008, 68:129-139.
34. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
35. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
36. Cooper G.S. Unraveling the etiology of systemic autoimmune diseases: peering into the preclinical phase of disease. J Rheumatol 2009, 36:1853-1855.
37. Pearson C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956, 91:95-101.
38. Toplak N., Avcin T. Vaccination of healthy subjects and autoantibodies: from mice through dogs to humans. Lupus 2009, 18:1186-1191.
39. Kitazawa J., Ohtani K., Shiotani M., Satoh A., Sugimoto K., Nomura Y., et al. Idiopathic thrombocytopenic purpura following measles-rubella-conjugated vaccine. Pediatr Int 2007, 49:688-689.
40. Martinuc Porobic J., Avcin T., Bozic B., Kuhar M., Cucnik S., Zupancic M., et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol 2005, 142:377-380.
41. Toplak N., Kveder T., Trampus-Bakija A., Subelj V., Cucnik S., Avcin T. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 2008, 8:134-138.
42. Merbl Y., Zucker-Toledano M., Quintana F.J., Cohen I.R. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007, 117:712-718.
43. Niu M.T., Ball R., Woo E.J., Burwen D.R., Knippen M., Braun M.M., et al. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine 2009, 27:290-297.
44. Kenney R.T., Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003, 2:167-188.
45. Thomas L., Good R.A. Studies on the generalized Shwartzman reaction: I. General observations concerning the phenomenon. J Exp Med 1952, 96:605-624.
46. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
47. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2010.
48. Janssens S., Beyaert R. Role of toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003, 16:637-646.
49. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589:1-13.
50. Hallman M., Ramet M., Ezekowitz R.A. Toll-like receptors as sensors of pathogens. Pediatr Res 2001, 50:315-321.
51. Fukui R., Saitoh S., Matsumoto F., Kozuka-Hata H., Oyama M., Tabeta K., et al. Unc93B1 biases toll-like receptor responses to nucleic acid in dendritic cells toward DNA - but against RNA-sensing. J Exp Med 2009, 206:1339-1350.
52. Becker H., Pavenstaedt H., Willeke P. Emerging treatment strategies and potential therapeutic targets in primary Sjogren's syndrome. Inflamm Allergy Drug Targets 2009.
53. Kono D.H., Haraldsson M.K., Lawson B.R., Pollard K.M., Koh Y.T., Du X., et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA 2009, 106:12061-12066.
54. Baylor NW. Public workshop: adjuvants and adjuvanted preventive and therapeutic vaccines for infectious disease indications. Presented in Bethesda, MD, December 2-3, 2008; 2008/2010.
55. Ashraf-Benson S., Wall G.C., Veach L.A. Serum sickness-like reaction associated with efalizumab. Ann Pharmacother 2009, 43:383-386.
56. OKeeffe D.T., Cooke R. Serum sickness like reaction in an 11-year-old boy. Ir J Med Sci 2009.
57. Broder K.R., Cortese M.M., Iskander J.K., Kretsinger K., Slade B.A., Brown K.H., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-34.
58. Apisarnthanarak A., Uyeki T.M., Miller E.R., Mundy L.M. Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis 2009, 49:e18-e22.
59. Dreesen D.W., Bernard K.W., Parker R.A., Deutsch A.J., Brown J. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 1986, 4:45-49.
60. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196:859-865.
61. Nydegger U.E., Davis J.S. Soluble immune complexes in human disease. CRC Crit Rev Clin Lab Sci 1980, 12:123-170.
62. Siegrist C.A. Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 2007, 137(Suppl. 1):S46-S50.
63. Begier E.M., Langford C.A., Sneller M.C., Wise R.P., Ball R., VAERS Working Group Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol 2004, 31:2181-2188.
64. Wise R.P., Salive M.E., Braun M.M., Mootrey G.T., Seward J.F., Rider L.G., et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000, 284:1271-1279.
65. Ravetch J.V. A full complement of receptors in immune complex diseases. J Clin Invest 2002, 110:1759-1761.
66. Paiva C.N., Arras R.H., Magalhaes E.S., Alves L.S., Lessa L.P., Silva M.H., et al. Migration inhibitory factor (MIF) released by macrophages upon recognition of immune complexes is critical to inflammation in Arthus reaction. J Leukoc Biol 2009, 85:855-861.
67. Valenta R., Mittermann I., Werfel T., Garn H., Renz H. Linking allergy to autoimmune disease. Trends Immunol 2009, 30:109-116.
68. Jurakic Toncic R., Marinovic B., Lipozencic J. Nonallergic hypersensitivity to nonsteroidal antiinflammatory drugs, angiotensin-converting enzyme inhibitors, radiocontrast media, local anesthetics, volume substitutes and medications used in general anesthesia. Acta Dermatovenerol Croat 2009, 17:54-69.
69. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
70. Korzeniowska-Kowal A., Witkowska D., Gamian A. Molecular mimicry of bacterial polysaccharides and their role in etiology of infectious and autoimmune diseases. Postepy Hig Med Dosw 2001, 55:211-232.
71. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison?. J Autoimmun 2000, 14:1-10.
72. Waisbren B.A. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med Hypotheses 2008, 70:346-348.
73. Nachamkin I., Allos B.M., Ho T. Campylobacter species and Guillain-Barre syndrome. Clin Microbiol Rev 1998, 11:555-567.
74. Haber P., Sejvar J., Mikaeloff Y., DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf 2009, 32:309-323.
75. Vucic S., Kiernan M.C., Cornblath D.R. Guillain-Barre syndrome: an update. J. Clin Neurosci 2009, 16:733-741.
76. Albert L.J., Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 1999, 341:2068-2074.
77. Ball R., Shadomy S.V., Meyer A., Huber B.T., Leffell M.S., Zachary A., et al. HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum 2009, 60:1179-1186.
78. Wraith D.C., Goldman M., Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 2003, 362:1659-1666.
79. Toivanen A., Granfors K., Lahesmaa-Rantala R., Toivanen P. Immunological and bacteriological aspects of reactive arthritis. Rheumatol Int 1989, 9:201-203.
80. Molloy E.S., Powell F.C., Doran M.F., Ryan J.G., Mulligan N.J., McCarthy C.J., et al. An unusual case of Behcet's syndrome: triggered by typhoid vaccination?. Clin Exp Rheumatol 2004, 22:S71-S74.
81. Sahin N., Salli A., Enginar A.U., Ugurlu H. Reactive arthritis following tetanus vaccination: a case report. Mod Rheumatol 2009, 19:209-211.
82. Valenzuela-Suarez H., Garcia-Guerrero J., Dominguez-Gordillo L., Diego-Fossas P.G., Rabago-Arredondo J., Navarro-Vargas L. A seventy-four-year-old man with bilateral conjunctival hyperemia, urinary symptoms, and secondary reactive arthritis following the administration of the BCG vaccine. Gac Med Mex 2008, 144:345-347.
83. Asakawa J., Kobayashi S., Kaneda K., Ogasawara H., Sugawara M., Yasuda M., et al. Reactive arthritis after influenza vaccination: report of a case. Mod Rheumatol 2005, 15:283-285.
84. Aksu K., Keser G., Doganavsargil E. Reactive arthritis following tetanus and rabies vaccinations. Rheumatol Int 2006, 27:209-210.
85. Crowe J.E. Genetic predisposition for adverse events after vaccination. J Infect Dis 2007, 196:176-177.
86. Reif D.M., McKinney B.A., Motsinger A.A., Chanock S.J., Edwards K.M., Rock M.T., et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008, 198:16-22.
87. Banac S., Franulovic J. Familial liability to complications after BCG vaccination. Acta Paediatr 1997, 86:899-902.
88. de Carvalho J.F., Pereira R.M., Shoenfeld Y. Systemic polyarteritis nodosa following hepatitis B vaccination. Eur J Intern Med 2008, 19:575-578.
89. Perumalswami P., Peng L., Odin J.A. Vaccination as a triggering event for autoimmune hepatitis. Semin Liver Dis 2009, 29:331-334.
90. Ravel G., Christ M., Horand F., Descotes J. Autoimmunity, environmental exposure and vaccination: is there a link?. Toxicology 2004, 196:211-216.
91. Durand C.M., Betancur C., Boeckers T.M., Bockmann J., Chaste P., Fauchereau F., et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007, 39:25-27.
92. Jamain S., Quach H., Betancur C., Rastam M., Colineaux C., Gillberg I.C., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003, 34:27-29.
93. Centers for Disease Control and Prevention (CDC), Vaccine Safety Datalink (VSD) Project; 2009.
94. National Vaccine Program Office, Department of Health and Human Services, A Comprehensive Review of Federal Vaccine Safety Programs and Public Health Activities; 2008/2010.
95. Rothman K.J., Greenland S., Lash T.L. Modern epidemiology 2008, Lippincott Williams and Wilkins, Philadelphia. 3rd ed.
96. Drexler S.K., Foxwell B.M. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2009.
97. Piyasirisilp S., Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol 2002, 15:333-338.
98. Mutter J., Yeter D. Kawasaki's disease, acrodynia, and mercury. Curr Med Chem 2008, 15:3000-3010.
99. Faure E. Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial hepatitis B virus polymerase play a role through molecular mimicry?. Med Hypotheses 2005, 65:509-520.